# Bristol-Myers Squibb vs Vertex Pharmaceuticals

URL: https://funkfolio.com/compare/bmy-vs-vrtx

> Bristol-Myers Squibb ($125.4B, P/E 13.9) and Vertex Pharmaceuticals ($135.4B, P/E 34.6) compared: size, valuation, margins, debt, cash and price change.

---

## Bristol-Myers Squibb vs Vertex Pharmaceuticals

Bristol-Myers Squibb (BMY), health care, and Vertex Pharmaceuticals (VRTX), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Vertex Pharmaceuticals is worth $135.4B on the stock market and Bristol-Myers Squibb $125.4B: Vertex Pharmaceuticals is valued at 8% more. Bristol-Myers Squibb trades at 13.9 times earnings and Vertex Pharmaceuticals at 34.6. Over the past year Bristol-Myers Squibb's share price has moved +33.7% and Vertex Pharmaceuticals's +23.5%.

### Key facts

- **Bristol-Myers Squibb market value:** $125.4B
- **Vertex Pharmaceuticals market value:** $135.4B
- **Bristol-Myers Squibb P/E:** 13.9
- **Vertex Pharmaceuticals P/E:** 34.6
- **Bristol-Myers Squibb revenue:** $48.2B FY to 2025-12-31
- **Vertex Pharmaceuticals revenue:** $12B FY to 2025-12-31
- **Superinvestors holding both:** 1

Market values as of 18 Nov 2026, 05:03 UTC.

Bristol-Myers Squibb vs Vertex Pharmaceuticals: every measure side by side

| Measure | Bristol-Myers Squibb | Vertex Pharmaceuticals |
| --- | --- | --- |
| Sector | Health Care | Health Care |
| Country | United States | United States |
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size |  |  |
| Market cap | $125.4B lower | $135.4B higher |
| Revenue | $48.2B higher | $12B lower |
| Earnings | $7.1B higher | $4B lower |
| Employees | 32,500 higher | 6,400 lower |
| Total assets | $90B higher | $25.6B lower |
| Valuation |  |  |
| P/E | 13.9 lower | 34.6 higher |
| P/S | 2.6 lower | 11.3 higher |
| P/B | 5.4 lower | 6.5 higher |
| Dividend yield | 4.00% higher | 0.00% lower |
| Profitability |  |  |
| Operating margin | — | 34.8% |
| Balance sheet |  |  |
| Net assets | $18.5B lower | $18.7B higher |
| Total liabilities | $71.5B higher | $7B lower |
| Total debt | $45.1B | — |
| Cash on hand | $10.2B higher | $5.1B lower |
| Price change |  |  |
| Today | -2.51% lower | -0.67% higher |
| 1 year | +33.7% higher | +23.5% lower |

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

### Share price over one year

Each company's share price rebased to 100 on Nov 17, 2025, so the two lines start together. Price only: dividends are not included. Last: Bristol-Myers Squibb 131.1, Vertex Pharmaceuticals 123.1.

- Bristol-Myers Squibb (BMY)
- Vertex Pharmaceuticals (VRTX)

Bristol-Myers Squibb and Vertex Pharmaceuticals share prices over one year, rebased to 100: Bristol-Myers Squibb ends at 131.1, Vertex Pharmaceuticals at 123.1.

**The chart as a table**

Month-end share prices rebased to 100

| Month end | BMY | VRTX |
| --- | --- | --- |
| Nov 28, 2025 | 105.1 | 99.9 |
| Dec 31, 2025 | 115.2 | 104.5 |
| Jan 30, 2026 | 117.6 | 108.3 |
| Feb 27, 2026 | 133.2 | 114.5 |
| Mar 31, 2026 | 129.6 | 102.9 |
| Apr 30, 2026 | 129.4 | 98.5 |
| May 29, 2026 | 122.2 | 103.1 |
| Jun 30, 2026 | 123.1 | 114.4 |
| Jul 31, 2026 | 139.5 | 109.9 |
| Aug 31, 2026 | 142.7 | 125.5 |
| Sep 30, 2026 | 133.3 | 120.5 |
| Oct 30, 2026 | 133.5 | 128.8 |
| Nov 17, 2026 | 131.1 | 123.1 |

### Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

#### Both (1)

- [Tweedy, Browne team](https://funkfolio.com/gurus/tweedy-browne) 0.2% / 1.1%

#### Bristol-Myers Squibb only (14)

- [Richard Pzena](https://funkfolio.com/gurus/richard-pzena) 2.6%
- [Thomas Kahn](https://funkfolio.com/gurus/thomas-kahn) 1.6%
- [Josef Lakonishok](https://funkfolio.com/gurus/josef-lakonishok) 1.1%
- [Primecap team](https://funkfolio.com/gurus/primecap) 1.0%
- [Bill Miller (founder)](https://funkfolio.com/gurus/bill-miller) 0.9%
- [Cliff Asness](https://funkfolio.com/gurus/cliff-asness) 0.6%
- [Mark Boyar](https://funkfolio.com/gurus/mark-boyar) 0.5%
- [John Rogers](https://funkfolio.com/gurus/john-rogers) 0.4%
- [John Overdeck and David Siegel (founders)](https://funkfolio.com/gurus/two-sigma) 0.4%
- [Jeremy Grantham (co-founder)](https://funkfolio.com/gurus/jeremy-grantham) 0.1%
- [Murray Stahl](https://funkfolio.com/gurus/murray-stahl) &lt;0.1%
- [Mairs & Power team](https://funkfolio.com/gurus/mairs-and-power) &lt;0.1%
- [Rajiv Jain](https://funkfolio.com/gurus/rajiv-jain) &lt;0.1%
- [Sarah Ketterer](https://funkfolio.com/gurus/sarah-ketterer) &lt;0.1%

#### Vertex Pharmaceuticals only (4)

- [Jim Simons (1938–2024)](https://funkfolio.com/gurus/jim-simons) 0.3%
- [Israel Englander](https://funkfolio.com/gurus/israel-englander) 0.2%
- [Ken Griffin](https://funkfolio.com/gurus/ken-griffin) 0.1%
- [Baillie Gifford team](https://funkfolio.com/gurus/baillie-gifford) 0.1%

Percentages are each holding's share of that investor's reported portfolio (under "Both": Bristol-Myers Squibb / Vertex Pharmaceuticals). [Who owns BMY](https://funkfolio.com/stock/BMY/superinvestors) · [Who owns VRTX](https://funkfolio.com/stock/VRTX/superinvestors)

### More on Bristol-Myers Squibb

- [Bristol-Myers Squibb (BMY) stock page](https://funkfolio.com/stock/BMY)
- [Bristol-Myers Squibb market cap](https://funkfolio.com/stock/BMY/market-cap)
- [Bristol-Myers Squibb revenue](https://funkfolio.com/stock/BMY/revenue)
- [Bristol-Myers Squibb P/E ratio](https://funkfolio.com/stock/BMY/pe-ratio)
- [Bristol-Myers Squibb operating margin](https://funkfolio.com/stock/BMY/operating-margin)
- [Bristol-Myers Squibb total debt](https://funkfolio.com/stock/BMY/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### More on Vertex Pharmaceuticals

- [Vertex Pharmaceuticals (VRTX) stock page](https://funkfolio.com/stock/VRTX)
- [Vertex Pharmaceuticals market cap](https://funkfolio.com/stock/VRTX/market-cap)
- [Vertex Pharmaceuticals revenue](https://funkfolio.com/stock/VRTX/revenue)
- [Vertex Pharmaceuticals P/E ratio](https://funkfolio.com/stock/VRTX/pe-ratio)
- [Vertex Pharmaceuticals operating margin](https://funkfolio.com/stock/VRTX/operating-margin)
- [Vertex Pharmaceuticals total debt](https://funkfolio.com/stock/VRTX/total-debt)
- [Largest health care companies](https://funkfolio.com/companies/sector/health-care)

### Further comparisons

#### Bristol-Myers Squibb against its closest peers

- [Bristol-Myers Squibb vs Medtronic](https://funkfolio.com/compare/bmy-vs-mdt)
- [Bristol-Myers Squibb vs Stryker](https://funkfolio.com/compare/bmy-vs-syk)
- [Bristol-Myers Squibb vs McKesson](https://funkfolio.com/compare/bmy-vs-mck)

#### Vertex Pharmaceuticals against its closest peers

- [Vertex Pharmaceuticals vs Medtronic](https://funkfolio.com/compare/mdt-vs-vrtx)
- [Vertex Pharmaceuticals vs Intuitive Surgical](https://funkfolio.com/compare/isrg-vs-vrtx)
- [Vertex Pharmaceuticals vs Danaher](https://funkfolio.com/compare/dhr-vs-vrtx)

### Learn

- [What market capitalization is and is not](https://funkfolio.com/learn/markets/market-capitalization)
- [P/E ratio explained](https://funkfolio.com/learn/stocks/pe-ratio)
- [Market cap vs enterprise value](https://funkfolio.com/learn/markets/market-cap-vs-enterprise-value)

### Questions and answers

**Which is bigger, Bristol-Myers Squibb or Vertex Pharmaceuticals?**

By market value, Vertex Pharmaceuticals is the larger: $135.4B against $125.4B for Bristol-Myers Squibb. By revenue in its latest fiscal year, Bristol-Myers Squibb is the larger: $48.2B against $12B for Vertex Pharmaceuticals.

**Which has the higher P/E ratio?**

Vertex Pharmaceuticals: 34.6, against 13.9 for Bristol-Myers Squibb. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.

**Which has the higher dividend yield?**

Bristol-Myers Squibb: 4.00%, against 0.00% for Vertex Pharmaceuticals. Dividend yield is the last twelve months' dividends as a share of today's share price.

**Which superinvestors own both Bristol-Myers Squibb and Vertex Pharmaceuticals?**

In their latest 13F filings, Tweedy, Browne team holds both.

### Cite this page

Funkfolio, “Bristol-Myers Squibb vs Vertex Pharmaceuticals”, data as of 18 November 2026. https://funkfolio.com/compare/bmy-vs-vrtx

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.
